Cannabis for Cancer Declaration seeks partners for canine cannabinoid trials

Cannabis for Cancer Declaration is looking for veterinary researchers and other partners to help launch controlled cannabinoid studies in dogs with cancer. The push follows a 2026 systematic review that found preclinical CBD data in canine cancers supports clinical investigation.

Why it matters: - Controlled clinical trials could help determine whether cannabinoids improve outcomes in dogs with cancer. - The work could also inform comparative oncology, a field the National Cancer Institute says can help advance treatments for dogs and humans. - Veterinary cancer research needs standardized products, dosing, safety data and oversight before cannabinoids can be considered as therapies.

What happened: - Cannabis for Cancer Declaration announced an effort to identify veterinary oncology researchers and other partners interested in developing controlled clinical studies of cannabinoids in dogs with cancer. - The initiative is seeking veterinary oncologists, veterinary schools, academic researchers, research institutions, animal cancer organizations, funders and other qualified parties. - The announcement came after a May 21, 2026 systematic review in Frontiers in Veterinary Science titled "Potential antitumor effect of cannabidiol (CBD) in canine oncology: a systematic review." - More information is available on the organization’s social media page.

The details: - Cannabis for Cancer Declaration says it wants to help qualified researchers move promising cannabinoid research toward clinical investigation. - Possible support includes financial assistance where feasible, research and literature support, public and pet-owner outreach, help finding collaborators and connections with groups interested in veterinary cannabinoid research. - The systematic review examined eight preclinical studies involving canine cancers, including lymphoma, mammary cancer, glioma, prostate cancer, osteosarcoma and urothelial carcinoma. - The review reported antiproliferative and pro-apoptotic effects from CBD across the studies. - The authors concluded the findings support clinical trials to study CBD pharmacology and potential antitumor efficacy in dogs with cancer. - The organization is open to research on CBD and other cannabinoids or cannabinoid formulations when supported by scientific evidence and appropriate veterinary oversight. - A 2025 randomized, placebo-controlled clinical study in dogs with lymphoma showed CBD/CBDA-rich hemp oil could be studied prospectively in canine cancer patients receiving chemotherapy. - That 2025 study focused on safety, tolerability and interactions with CHOP chemotherapy, not on whether cannabinoids directly fight cancer.

Between the lines: - The organization is trying to move the conversation from preclinical signals and anecdotal reports to controlled efficacy trials. - The timing suggests the group sees the 2026 review as enough of a scientific opening to start building a research network. - The National Cancer Institute’s Comparative Oncology Program gives the effort a broader scientific backdrop, since naturally occurring cancers in pet dogs can offer insights relevant to human medicine.

What's next: - Cannabis for Cancer Declaration wants to connect with investigators who see scientific merit in the question and can help design appropriate studies. - Any future trials would need institutional oversight, standardized products, careful dosing, safety monitoring, drug-interaction review and animal-welfare protections. - The organization says preclinical research and anecdotal reports do not establish cannabinoids as effective cancer treatments in dogs.

The bottom line: - Cannabis for Cancer Declaration is trying to turn early cannabinoid findings in canine cancer into rigorous clinical research, with the goal of learning whether the compounds can safely and effectively help dogs with cancer.